Dayvigo (Lemborexant) Side Effects, Withdrawal, and Discontinuation: What Women Need to Know

What Is Lemborexant and Why Women Are Prescribed It

Lemborexant blocks both orexin-1 and orexin-2 receptors in the brain, quieting the wake-promoting signals that keep you alert at night. The FDA approved it in December 2019 under the brand name Dayvigo for adults with insomnia characterized by difficulty with sleep onset and maintenance.

Women are diagnosed with insomnia at roughly 1.4 times the rate of men, a disparity driven partly by sex hormone fluctuations across the menstrual cycle, postpartum hormone shifts, and the vasomotor symptoms of perimenopause and menopause. Because lemborexant targets the orexin wake-drive system rather than broadly sedating the brain, it was marketed as having a more favorable side-effect profile than older agents such as zolpidem. That claim holds up reasonably well, but it is not without nuance.

How Orexin Biology Differs in Women

Orexin neurons interact with estrogen receptors in the hypothalamus. Estrogen appears to modulate orexin tone, which may partly explain why insomnia worsens during perimenopause as estrogen levels drop. Animal studies show sex differences in orexin-1 receptor density, but direct pharmacokinetic data in women versus men for lemborexant are limited. The prescribing information does not report a sex-based dose adjustment, though women generally metabolize CYP3A4 substrates (lemborexant is primarily CYP3A4) slightly more slowly than men, which may extend the drug's half-life and worsen next-day sedation. This sex difference in CYP3A4 activity has been documented for zolpidem, leading the FDA to halve the recommended morning dose for women; no equivalent label change has been made for lemborexant yet. This is an evidence gap you deserve to know about.

Common Dayvigo Side Effects

The 10 mg dose produces somnolence (drowsiness carrying into the next day) in approximately 10-12% of patients in the SUNRISE-1 trial, compared with 1% on placebo. At the 5 mg dose the incidence dropped to about 7%. These numbers come from a 30-night randomized controlled trial of 266 adults, so they reflect relatively short-term exposure.

Next-Day Sleepiness

This is the side effect most likely to affect your daily function. A driving-simulation substudy within SUNRISE-1 found statistically significant impairment of driving ability at 7.5 hours after the 10 mg dose. The FDA label states you should not drive or operate heavy machinery until you are "fully awake." In practical terms, that means planning for at least 7 hours in bed, ideally 8, before you need to get behind the wheel.

Women may be at somewhat higher risk of next-day impairment than men because the drug's active metabolites may clear more slowly, though lemborexant-specific female pharmacokinetic data in humans remain sparse.

Sleep-Related Events: Parasomnias and Dream Changes

About 2-4% of patients in clinical trials reported abnormal dreams or vivid nightmares. Sleep paralysis (brief inability to move when falling asleep or waking) was reported in under 2% of participants. Hypnagogic or hypnopompic hallucinations (brief sensory events at sleep onset or offset) occurred in a small number of patients at the 10 mg dose.

These events mirror what is seen with other DORA drugs such as suvorexant (Belsomra). If you experience sleep paralysis, the standard guidance is to remain calm as it resolves spontaneously within seconds to a couple of minutes. Repeated episodes are a reason to contact your prescriber about dose reduction to 5 mg or switching agents.

Headache and Fatigue

Headache occurred in approximately 5% of lemborexant-treated patients versus 4% on placebo in SUNRISE-1, making it a marginal difference that did not reach significance. Fatigue was more pronounced at the 10 mg dose. Women who already experience menstrual-cycle-related migraines or perimenopausal headaches may find that lemborexant's residual sedation amplifies morning fatigue on high-headache days.

Rare Side Effects: What the Label and FAERS Data Show

The FDA Adverse Event Reporting System (FAERS) collects voluntary post-market reports, so incidence estimates from FAERS are not directly comparable to clinical-trial rates. Patterns in FAERS data for lemborexant through 2023 show case reports of the following rare events.

Sleep Driving and Complex Sleep Behaviors

The FDA added a boxed warning in April 2019 (applied class-wide to all sleep aids, including lemborexant upon approval) for complex sleep behaviors including sleep walking, sleep driving, and sleep-related eating. These behaviors have occurred with DORA drugs at therapeutic doses, particularly in patients who also use alcohol, other CNS depressants, or have underlying sleep disorders such as REM sleep behavior disorder.

Women with a personal or family history of sleepwalking are at elevated risk. If you experience any episode of acting out behaviors during sleep, stop the medication and contact your prescriber the next day.

Cataplexy-Like Episodes

Because orexin signaling is involved in muscle tone, very rare cataplexy-like episodes (sudden brief muscle weakness triggered by emotion) have been reported with DORAs in post-market surveillance. The incidence is not precisely quantified but appears to be well under 0.1% based on FAERS case volume relative to prescription volume. This is distinct from true narcolepsy-cataplexy, which requires orexin deficiency of a different magnitude.

Psychiatric Events

A small number of FAERS reports describe transient depressive symptoms, suicidal ideation, and anxiety in patients using lemborexant. The prescribing information advises monitoring for worsening depression. Women have higher baseline rates of major depressive disorder and anxiety disorders, so this rare signal deserves attention even though causality has not been established.

Dayvigo Withdrawal and Discontinuation Syndrome

This is the section most searches land on, so here is the direct answer: lemborexant does not produce a physiological withdrawal syndrome in the classic sense that benzodiazepines or Z-drugs do. There is no documented seizure risk, no autonomic instability, and no reported life-threatening discontinuation event attributable to lemborexant in published trials or FAERS.

What does happen is rebound insomnia.

What Rebound Insomnia Looks Like After Lemborexant

Rebound insomnia is a temporary worsening of sleep beyond your original baseline that occurs in the first few nights after stopping a sleep aid. In the SUNRISE-2 trial (12 months, n=949), the discontinuation phase showed that objective sleep measures (polysomnography latency to persistent sleep and wake after sleep onset) did return toward pre-treatment values after stopping lemborexant. The investigators did not report severe rebound; subjective sleep quality at the end of a 30-day run-out period was not dramatically worse than pre-study baseline.

Compared with zolpidem, which is associated with significant rebound insomnia in many patients, the rebound with lemborexant appears milder. However, "milder" is not "absent." You may have two to five difficult nights after stopping, and knowing this in advance helps prevent the nocebo effect from turning a temporary sleep disruption into a decision to restart the drug unnecessarily.

Tapering vs. Abrupt Discontinuation

The prescribing information does not mandate a taper. The current clinical standard is that, after short-term use (weeks), abrupt discontinuation is generally well tolerated. After longer use (months), a brief dose step-down from 10 mg to 5 mg for one to two weeks before stopping is a reasonable and commonly recommended approach, though there is no randomized trial directly comparing taper versus abrupt stop for lemborexant.

The WomanRx clinical framework for lemborexant discontinuation by use duration:

| Duration of use | Suggested approach | |---|---| | <4 weeks | Abrupt stop is reasonable; expect 1-3 rough nights | | 4 weeks to 3 months | Step down to 5 mg for 1-2 weeks, then stop | | >3 months | Discuss individualized taper with prescriber; concurrent behavioral therapy for insomnia (CBT-I) strongly recommended |

This framework is based on expert consensus and pharmacological reasoning, not a dedicated tapering trial. Ask your prescriber to walk through which category applies to you.

Psychological Dependence vs. Physical Withdrawal

Psychological reliance on any sleep aid is real. A drug that helps you sleep becomes tied, in your brain, to the expectation of sleep, and removing it can generate anxiety about sleep itself. This anxiety is not a pharmacological withdrawal symptom, but it feels just as new. Behavioral interventions (sleep restriction, stimulus control, cognitive restructuring) delivered as CBT-I have a response rate of 70-80% for chronic insomnia and address the psychological component that no drug discontinuation plan touches.

Sex-Specific Pharmacokinetics and Dosing Considerations

Lemborexant is metabolized primarily by CYP3A4, with minor contributions from CYP3A5. The mean elimination half-life of the parent drug is approximately 17-19 hours; active metabolites extend exposure further.

Hormonal Contraceptives and CYP3A4 Interaction

Hormonal contraceptives are weak CYP3A4 inducers. In theory, combined oral contraceptives could modestly accelerate lemborexant clearance and reduce its efficacy, though this interaction has not been studied directly. The prescribing information does not list hormonal contraceptives as a clinically significant interaction. If you feel the drug is working less effectively after starting combined hormonal contraception, report it to your prescriber.

Menstrual Cycle Phase Effects

During the luteal phase, progesterone metabolites (allopregnanolone) potentiate GABA-A receptors, which may add to sedation when combined with lemborexant. Some women notice that sleepiness the morning after a dose feels heavier in the week before their period. This has not been studied in a controlled trial; it is physiologically plausible and worth tracking in a sleep diary.

Perimenopausal and Postmenopausal Women

Insomnia is reported by 40-60% of perimenopausal women and is driven by a combination of vasomotor symptoms, declining estrogen and progesterone, and altered circadian rhythm. Lemborexant addresses the wake-drive component but does nothing to reduce hot flashes. If hot flash-related awakenings are your primary problem, menopausal hormone therapy (MHT) or non-hormonal options such as fezolinetant address the root cause more directly.

A major evidence gap exists here: the SUNRISE trials enrolled adults broadly, but the published data do not provide a subgroup analysis specifically for perimenopausal or postmenopausal women. The Menopause Society 2023 position statement on non-hormonal insomnia treatment acknowledges DORA drugs as an option for menopause-related insomnia but notes the paucity of data specific to this population.

PCOS, Metabolic Health, and Sleep

Women with polycystic ovary syndrome have a disproportionately high prevalence of sleep-disordered breathing and insomnia. A 2012 study in the Journal of Clinical Endocrinology and Metabolism found obstructive sleep apnea (OSA) in 35-40% of obese women with PCOS, compared with rates well below 5% in age-matched controls.

This matters for lemborexant for two reasons. First, DORA drugs can theoretically suppress arousal from hypoxic events in patients with undiagnosed OSA. The prescribing information carries a precaution against use in patients with severe OSA. If you have PCOS and have not been screened for sleep apnea, that evaluation should happen before starting any sedative-hypnotic. Second, PCOS is associated with chronic sleep deprivation, which worsens insulin resistance. Better sleep quality is metabolically beneficial, but only if the sleep aid does not suppress upper-airway protective reflexes.

Pregnancy, Lactation, and Contraception

Lemborexant is not recommended during pregnancy.

Pregnancy Safety Data

The FDA label classifies lemborexant under the newer Pregnancy and Lactation Labeling Rule (PLLR) rather than a letter category, but the available evidence is concerning. Animal reproduction studies at doses producing exposures approximately 60 times the human 10 mg dose showed increased fetal loss and developmental abnormalities in rats. No adequate, well-controlled studies exist in pregnant women. Given the lack of human safety data, most clinicians and the prescribing information recommend avoiding lemborexant in pregnancy.

If you become pregnant while taking lemborexant, stop the drug and contact your OB-GYN or maternal-fetal medicine specialist. Insomnia during pregnancy is common, and CBT-I has the strongest evidence for safety in pregnancy, with a meta-analysis published in Sleep Medicine Reviews showing significant improvement in sleep outcomes without drug exposure.

Lactation

It is not known whether lemborexant or its metabolites are excreted in human milk. Animal studies show transfer to rat milk. Given the long half-life (17-19 hours for the parent compound), potential accumulation in an infant and sedation risk are concerns. LactMed does not currently have a specific lemborexant entry, and the prescribing information advises that the developmental and health benefits of breastfeeding should be weighed against the potential risk. If you are breastfeeding and need pharmacological sleep support, discuss alternatives with your prescriber. Short-term low-dose doxylamine has more human lactation data, though not without its own limitations.

Contraception

Lemborexant is not a known teratogen at therapeutic doses in humans, but given animal data suggesting fetal risk and the complete absence of human pregnancy data, women of reproductive age should use reliable contraception while taking it. If you are planning conception, a planned discontinuation and transition to CBT-I well before attempting pregnancy is advisable.

Who This Is Right For (and Who Should Think Twice)

Life Stages and Conditions Where Lemborexant May Be Appropriate

Reproductive-age women with chronic insomnia and no pregnancy plans. The drug's favorable abuse-potential profile (Schedule IV, same as zolpidem, but with less reinforcing pharmacology according to preclinical data) makes it a reasonable short-to-medium-term option when CBT-I alone has not been sufficient. Use reliable contraception.

Perimenopausal women whose insomnia is not driven primarily by hot flashes. If your sleep problem is mainly difficulty staying asleep despite reasonable temperature control and no hot-flash awakenings, a DORA may help more than adding another layer of hormone therapy.

Postmenopausal women with stable health and no OSA. OSA screening is important in this group because postmenopausal women lose the protective ventilatory effects of progesterone and OSA prevalence rises.

Who Should Think Twice or Avoid It

Women who are pregnant or planning pregnancy in the near term. No human safety data; animal harm signal. Stop before conception.

Women who are breastfeeding. Transfer to milk is unknown; infant sedation risk cannot be excluded.

Women with undiagnosed or severe obstructive sleep apnea. Get the sleep study first.

Women taking strong CYP3A4 inhibitors such as ketoconazole, clarithromycin, or ritonavir. These drugs can dramatically increase lemborexant plasma levels, potentially to dangerous sedative concentrations. The prescribing information contraindicates co-administration with strong CYP3A4 inhibitors.

Women with narcolepsy. Blocking orexin signaling in someone who already has insufficient orexin activity risks worsening cataplexy and excessive daytime sleepiness.

Women who consume alcohol in the evenings. Alcohol is a CNS depressant that potentiates lemborexant's sedative effects and meaningfully increases the risk of complex sleep behaviors and next-day impairment. The combination is not recommended.

Managing Side Effects in Practice

If next-day drowsiness is your main complaint, the first step is stepping down from 10 mg to 5 mg before abandoning the drug. Many patients find 5 mg adequate for sleep maintenance with meaningfully less morning sedation.

For sleep paralysis or abnormal dreams that are distressing, dose reduction is also the standard first move. Switching to a different drug class (e.g., a low-dose sedating antidepressant such as doxepin 3-6 mg, which is FDA-approved for sleep maintenance insomnia) is an alternative if DORA-class side effects persist.

Tracking side effects in a simple daily log (time in bed, time to sleep, morning alertness on a 1-5 scale, any unusual events) gives your prescriber the data needed to make an informed adjustment rather than relying on memory during a brief appointment.

Ask your prescriber to review your full medication list for CYP3A4 interactions at initiation and again any time a new drug is added, because the risk of elevated lemborexant levels is real and underappreciated in practice.

A Clinical Note on the Evidence Gap for Women

WomanRx editorial board member Maya Okafor, MD, OB-GYN, notes: "The SUNRISE trials were not powered to detect sex differences in next-day impairment or rebound insomnia severity, and the menopause subgroup was not separately analyzed. Until that data exists, women in perimenopause should be counseled that their experience may differ from the published averages, and that starting at 5 mg is a sensible default."

Women have historically been under-enrolled in sleep pharmacology trials, partly because of concerns about pregnancy and partly because earlier trial designs used male participants as the default. The SUNRISE-1 and SUNRISE-2 trials did include women, but sex-stratified pharmacokinetic and efficacy data in the published reports are limited. Extrapolating from pooled results to a specific woman in perimenopause or with PCOS requires clinical judgment that goes beyond the label.